儿童费城染色体阳性急性淋巴细胞白血病中SLC2A5过表达
基于已发表基因表达谱的微阵列分析显示,SLC2A5在儿童费城染色体阳性急性淋巴细胞白血病(Ph+ALL)中上调,且其高表达与疾病复发、早期复发、完全缓解期缩短及治疗后微小残留病(MRD)阳性相关。验证队列证实了mRNA和蛋白水平的过表达及与MRD状态的相关性;机制研究提示BCR-ABL1激酶可能通过MYC调控SLC2A5,酪氨酸激酶抑制剂(TKI)伊马替尼和达沙替尼可抑制SLC2A5表达及细胞对果糖的摄取。
要点
- SLC2A5在儿童Ph+ALL中mRNA和蛋白水平均过表达。
- SLC2A5高表达与3年内复发、早期复发、完全缓解期缩短及治疗后MRD阳性相关。
- 伊马替尼和达沙替尼可抑制SLC2A5表达及细胞对果糖的摄取。
核心结论
- SLC2A5在儿童Ph+ALL中上调,其表达与MRD状态等临床因素相关;TKI抑制SLC2A5表达,抑制果糖利用可能参与TKI诱导的Ph+ALL细胞毒性;靶向SLC2A5在B-ALL治疗中可能具有前景,尤其是SLC2A5高表达的Ph+ALL患者。
研究设计与样本
- 基于已发表基因表达谱的微阵列分析,并在儿童B-ALL验证队列中验证SLC2A5的mRNA和蛋白表达及与MRD状态的相关性。
- 机制研究使用人Ph+ALL细胞系。
主要发现
- 微阵列分析发现SLC2A5在Ph+ALL中上调,在伴t(1;19)或11q23突变的儿童B-ALL中显著下调。
- SLC2A5高表达见于3年内疾病复发、早期复发、完全缓解期缩短及治疗后MRD阳性的患者。
- 验证队列证实Ph+ALL中SLC2A5 mRNA和蛋白水平过表达,并验证了SLC2A5表达与MRD状态的相关性。
- 机制研究显示BCR-ABL1激酶可能通过MYC调控SLC2A5表达;伊马替尼和达沙替尼抑制SLC2A5表达及细胞对果糖的摄取;果糖保护肿瘤细胞免于营养缺乏和药物诱导的细胞死亡。
临床怎么用
- 作者认为靶向SLC2A5在B-ALL治疗中可能具有前景,尤其是SLC2A5高表达的Ph+ALL患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To study glycolysis/glycogenesis-related genes expression in childhood B-cell acute lymphoblastic leukaemia (B-ALL), we performed a microarray-based analysis using published gene expression profiles. We found that SLC2A5, which encodes solute carrier family 2 member 5 (SLC2A5, previously termed GLUT5) that facilitates cell fructose uptake, was up-regulated in Philadelphia chromosome-positive ALL (Ph+ALL). Microarray-based analyses also suggested that SLC2A5 expression was significantly down-regulated in childhood B-ALL with t(1;19) or 11q23 mutation. High SLC2A5 expression was found in patients who had disease recurrence within 3 years, early relapse, shortened complete remission duration and positive minimal residue disease (MRD) status after treatment. SLC2A5 overexpression at both the mRNA and protein level in Ph+ALL was confirmed in a validation cohort of childhood B-ALL. We also validated the correlation of SLC2A5 expression and MRD status. A mechanistic study using a human Ph+ALL cell line showed that BCR-ABL1 kinase might regulate SLC2A5 expression via MYC. The tyrosine kinase inhibitors (TKIs) imatinib and dasatinib repressed SLC2A5 expression and the cell uptake of fructose. Fructose protected the tumour cells from nutrition deficiency and drug-induced cell death. Overall, our findings showed that SLC2A5 was up-regulated in childhood Ph+ALL. SLC2A5 expression correlated with childhood B-ALL clinical factors, such as MRD status. Given that TKIs could inhibit SLC2A5 expression, repression of fructose utility after TKI treatment contributes to TKI-induced Ph+ALL cytotoxicity. Targeting SLC2A5 might be promising in B-ALL treatment, especially for Ph+ALL patients with high SLC2A5 expression.
引用
- Zhao P, Huang J, Zhang D, et al. SLC2A5 overexpression in childhood philadelphia chromosome-positive acute lymphoblastic leukaemia. Br J Haematol. 2018. PMID: 30272826. doi:10.1111/bjh.15580
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。